Results 101 to 110 of about 5,527 (127)

Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database. [PDF]

Alzheimers Res Ther
Irizarry M, Surick I, Michael A, D Kramer L.   +3 more
europepmc   +1 more source

Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance. [PDF]

Alzheimers Res Ther
Donati M, Boccia A, De Ponti F, Poluzzi E, Raschi E.   +4 more
europepmc   +1 more source

Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan [PDF]

AJ Avery, AK Banerjee, AS Rogers, E Lopez-Gonzalez, Japanese Association of Pharmaceutical Medicine, K Kanmuri, L Hazell, L Macdougall, M Bäckström, M Iwasaki, T Watanabe, T Watanabe   +11 more
core   +1 more source

Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year. [PDF]

Am J Clin Dermatol
Hu W, Thornton M, Livingston RA.
europepmc   +1 more source

Safety and Effectiveness of Vibegron in Japanese Patients With Overactive Bladder: A Japanese Postmarketing Survey. [PDF]

Low Urin Tract Symptoms
Yoshimura S, Yagi H, Abe K, Yamasaki M.
europepmc   +1 more source

Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System. [PDF]

BMJ Open
Alami A, Pérez-Lloret S, Mattison DR.
europepmc   +1 more source

Postmarketing safety evaluation of pemetrexed using FAERS and JADER databases. [PDF]

Sci Rep
Lv L, Wu X, Ren Y, Guo Y, Wang H, Li X.
europepmc   +1 more source

Points to Consider on the Use of Medicines in Pregnancy Throughout the Product Lifecycle Based on Global Regulatory Guidance. [PDF]

Ther Innov Regul Sci
Alexe A, Wurst K, Balramsingh-Harry L, Apara O, Abramova N, Eisele O, Fernandes MFS, Garg A, Kovacs B, Lewis D.   +9 more
europepmc   +1 more source

Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20-week interim analysis of a postmarketing surveillance study. [PDF]

J Dermatol
Tada Y, Sugiura Y, Kamishima M, Tanaka Y, Tsuchiya H, Masuda J, Yamanaka K.   +6 more
europepmc   +1 more source

Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor [PDF]

Ali, Ayad K
core   +2 more sources